In order to advance therapeutic applications of nicotinic ligands, continuing research efforts are being directed toward the identification and characterization of novel nicotinic acetylcholine receptor (nAChR) ligands that are both potent and subtype selective. Herein we report the synthesis and pharmacological evaluation of members of a new series of 3-alkoxy-5-aminopyridine derivatives that display good selectivity for the α4β2-nAChR subtype based on ligand binding and functional evaluations. The most potent ligand in this series, compound 64, showed high radioligand binding affinity and selectivity for rat α4β2-nAChR with a K(i) value of 1.2 nM and 4700-fold selectivity for α4β2- over α3β4-nAChR, and ∼100-fold selectivity for functional, high-sensitivity, human α4β2-nAChR over α3β4*-nAChR. In the mouse forced swim test, compound 64 exhibited antidepressant-like effects. Structure-activity relationship (SAR) analyses suggest that the introduction of additional substituents to the amino group present on the pyridine ring of the N-demethylated analogue of compound 17 can provide potent α4β2-nAChR-selective ligands for possible use in treatment of neurological and psychiatric disorders including depression.
In order to advance therapeutic applications of nicotinic ligands, continuing resn class="Chemical">earch efforts are being directed toward the identification and characterization of novel nicotinic acetylcholine receptor (nAChR) ligands that are both potent and subtype selective. Herein we report the synthesis and pharmacological evaluation of members of a new series of 3-alkoxy-5-aminopyridine derivatives that display good selectivity for the α4β2-nAChR subtype based on ligand binding and functional evaluations. The most potent ligand in this series, compound 64, showed high radioligand binding affinity and selectivity for rat α4β2-nAChR with a K(i) value of 1.2 nM and 4700-fold selectivity for α4β2- over α3β4-nAChR, and ∼100-fold selectivity for functional, high-sensitivity, human α4β2-nAChR over α3β4*-nAChR. In the mouse forced swim test, compound 64 exhibited antidepressant-like effects. Structure-activity relationship (SAR) analyses suggest that the introduction of additional substituents to the amino group present on the pyridine ring of the N-demethylated analogue of compound 17 can provide potent α4β2-nAChR-selective ligands for possible use in treatment of neurological and psychiatric disorders including depression.
Authors: Yi Fan; Rayomand Unwalla; Rajiah A Denny; Li Di; Edward H Kerns; David J Diller; Christine Humblet Journal: J Chem Inf Model Date: 2010-06-28 Impact factor: 4.956
Authors: M Bencherif; M E Lovette; K W Fowler; S Arrington; L Reeves; W S Caldwell; P M Lippiello Journal: J Pharmacol Exp Ther Date: 1996-12 Impact factor: 4.030
Authors: J P Sullivan; D Donnelly-Roberts; C A Briggs; D J Anderson; M Gopalakrishnan; M Piattoni-Kaplan; J E Campbell; D G McKenna; E Molinari; A M Hettinger; D S Garvey; J T Wasicak; M W Holladay; M Williams; S P Arneric Journal: Neuropharmacology Date: 1996-06 Impact factor: 5.250
Authors: M Imad Damaj; F Ivy Carroll; J Brek Eaton; Hernan A Navarro; Bruce E Blough; Sadiq Mirza; Ronald J Lukas; Billy R Martin Journal: Mol Pharmacol Date: 2004-09 Impact factor: 4.436
Authors: Amir H Rezvani; Olga Timofeeva; Hannah G Sexton; Damien DeCuir; Yingxian Xiao; Christopher J Gordon; Kenneth J Kellar; Edward D Levin Journal: Eur J Pharmacol Date: 2012-02-24 Impact factor: 4.432
Authors: Jianhua Liu; Li-Fang Yu; J Brek Eaton; Barbara Caldarone; Katie Cavino; Christina Ruiz; Matthew Terry; Allison Fedolak; Daguang Wang; Afshin Ghavami; David A Lowe; Dani Brunner; Ronald J Lukas; Alan P Kozikowski Journal: J Med Chem Date: 2011-09-30 Impact factor: 7.446
Authors: Edward D Levin; Hannah G Sexton; Karen Gordon; Christopher J Gordon; Yingxian Xiao; Kenneth J Kellar; Venkata Mahidhar Yenugonda; Yong Liu; Michael P White; Mikell Paige; Milton L Brown; Amir H Rezvani Journal: Eur J Pharmacol Date: 2013-09-12 Impact factor: 4.432